Hostname: page-component-586b7cd67f-t7fkt Total loading time: 0 Render date: 2024-11-28T22:34:27.581Z Has data issue: false hasContentIssue false
  • English
  • Français

Epidemiological Surveillance of Amyotrophic Lateral Sclerosis in Saguenay Region

Published online by Cambridge University Press:  23 September 2014

Émilie Lareau-Trudel ,
Élizabeth Fortin ,
Marianne Gauthier ,
Sarah Lavoie ,
Érika Morissette  and
Jean Mathieu
Émilie Lareau-Trudel
Affiliation:
Faculty of Medicine and Health Sciences, Sherbrooke University
Élizabeth Fortin
Affiliation:
Faculty of Medicine and Health Sciences, Sherbrooke University
Marianne Gauthier
Affiliation:
Faculty of Medicine and Health Sciences, Sherbrooke University
Sarah Lavoie
Affiliation:
Faculty of Medicine and Health Sciences, Sherbrooke University
Érika Morissette
Affiliation:
Faculty of Medicine and Health Sciences, Sherbrooke University
Jean Mathieu*
Affiliation:
Faculty of Medicine and Health Sciences, Sherbrooke University Neuromuscular Clinic, Jonquiere Hospital, Quebec, Canada
*
Neuromuscular Clinic, Carrefour de Santé de Jonquière, 2230 rue de l'Hôpital, Jonquière, Québec, G7X 7X2, Canada. Email: [email protected]
Rights & Permissions [Opens in a new window]

Abstract:

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Objectives:

The Neuromuscular Registry of Saguenay-Lac-Saint-Jean (SLSJ), Québec, Canada was established for epidemiological surveillance of neuromuscular disorders including amyotrophic lateral sclerosis (ALS). The objectives of this study are to analyze the ALS clinical characteristics of the SLSJ population and to determine the incidence rate over time by five year periods since 1985.

Methods:

The Registry was validated by a review of the medical records maintained at the CSSS de Chicoutimi, the regional university hospital and, by the estimation of the number of hospitalizations for ALS patients using the Quebec Hospital inpatient database (MED-ECHO).

Results:

A total of 109 patients were included. Overall, the clinical features of ALS observed in SLSJ population are similar to those described in the literature. We observed a significant increase in the incidence rate of ALS during the 2005-2009 period compared with the previous periods. This is due to a significant increase in the incidence rate among the ≥65 years old group, from 4.68 per 100,000 persons/year (CI 95% 2.88-6.48) during 1985-2004 period to 12.22 (CI 95% 7.43-17.02) during 2005-2009 period.

Conclusion:

Given the small size of the SLSJ population, a longer observation period will be needed to confirm a new steady state incidence of ALS in this region.

Type
Original Article
Information
Canadian Journal of Neurological Sciences , Volume 40 , Issue 5 , September 2013 , pp. 705 - 709
Copyright
Copyright © The Canadian Journal of Neurological 2013

References

1.Gunnarson, LG, Lindberg, G, Söderfelt, B, Axelson, O.The mortality of motor neuron disease in Sweden. Arch Neurol. 1990;47:42–6.CrossRefGoogle Scholar
2.Neilson, S, Gunnarson, LG, Robinson, I.Rising mortality from motor neurone disease in Sweden 1961-1990: the relative role of increased population life expectancy and environmental factors. Acta Neurol Scand. 1994;90:150–9.CrossRefGoogle ScholarPubMed
3.Neilson, S, Robinson, I, Nymoen, EH.Longitudinal analysis of amyotrophic lateral sclerosis mortality in Norway, 1966-1989: evidence for a susceptible subpopulation. J Neurol Sci. 1994;122:148–54.Google Scholar
4.McGuire, V, Longstreth, WT Jr, Koepsell, TD, van Belle, G.Incidence of amyotrophic lateral sclerosis in three counties in western Washington state. Neurology. 1996;47:571–3.Google Scholar
5.Neilson, S, Robinson, I, Hunter, M.Longitudinal gompertzian analysis of ALS mortality in England and Wales, 1963-1989: estimates of susceptibility in the general population. Mech Aging Dev. 1992;64:201–16.CrossRefGoogle ScholarPubMed
6.Lilienfeld, DE, Chan, E, Ehland, J, et al.Rising mortality from motor neuron disease in the USA, 1962-84. Lancet. 1989;1:710–2.Google Scholar
7.Cima, V, Logroscino, G, D'Ascenzo, C, et al.Epidemiology of ALS in Padova district, Italy, from 1992 to 2005. Eur J Neurol. 2009;16:920–4.CrossRefGoogle ScholarPubMed
8.Fang, F, Valdimarsdóttir, U, Bellocco, R, et al.Amyotrophic lateral sclerosis in Sweden, 1991-2005. Arch Neurol. 2009;66:515–9.Google Scholar
9.Murphy, M, Quinn, S, Young, J, Parkin, P, Taylor, B.Increasing incidence of ALS in Canterbury, New Zealand: a 22-year study. Neurology. 2008;71:1889–95.CrossRefGoogle ScholarPubMed
10.Noonan, CW, White, MC, Thurman, D, et al.Temporal and geographic variation in United States motor neuron disease mortality, 1969-1998, Neurology. 2005;64:1215–21.Google Scholar
11.Seljeseth, YM, Vollset, SE, Tysnes, OB.Increasing mortality from amyotrophic lateral sclerosis in Norway. Neurology. 2000;55:1262–6.CrossRefGoogle ScholarPubMed
12.Forbes, RB, Colville, S, Parratt, J, Swingler, RJ.The incidence of motor neuron disease in Scotland. J Neurol. 2007;254:866–9.CrossRefGoogle ScholarPubMed
13.Kihira, T, Yoshida, S, Kondo, T, et al.An increase in ALS incidence on the Kii Peninsula, 1960-2009: a possible link to change in drinking water source. Amyotroph Lateral Scler. 2012;13(4):347–50.Google Scholar
14.Pradat, P-F, Attarian, S, Camdessanché, JP, et al.La recherche sur la SLA en 2009: Compte rendu du groupe bibliographique de la coordination des centres SLA. Rev Neurol. 2010;166:683–98.Google Scholar
15.Brooks, BR, Miller, RG, Swash, M, Munsat, TL; World Federation of Neurology Research Group on Motor Neuron Diseases. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler other Motor Neuron disord. 2000;1(5):293–9.Google Scholar
16.Monfared, AA, Lelorier, J.Accuracy and validity of using medical claims data to identify episodes of hospitalizations in patients with COPD. Pharmacoepidemiol Drug Saf. 2006;15(1):19–29.CrossRefGoogle ScholarPubMed
17.Worms, PM.The epidemiology of motor neuron diseases: a review of recent studies. J Neurol Sci. 2001;191:3–9.Google Scholar
18.Logroscino, G, Traynor, BJ, Hardiman, O, et al.Incidence of amyotrophic lateral sclerosis in Europe. J Neurol Neurosurg Psychiatry. 2010;81:385–90.CrossRefGoogle ScholarPubMed
19.Armon, C.An evidence-based medicine approach to the evaluation of the role of exogenous risk factors in sporadic amyotrophic lateral sclerosis. Neuroepidemiology. 2003;22:217–28.Google Scholar
20.de Jong, SW, Huisman, MH, Sutedja, NA, et al.Smoking, alcohol consumption, and the risk of amyotrophic lateral sclerosis: a population-based study. Am J Epidemiol. 2012;176(3):233–9.CrossRefGoogle ScholarPubMed
21.Laberge, AM, Michaud, J, Richter, A, et al.Population history and its impact on medical genetics in Quebec. Clin Genet. 2005:68:287–301.CrossRefGoogle ScholarPubMed
22.Soriani, MH, Desnuelle, C.Épidémiologie de la SLA. Rev Neurol. 2009;165:627–40.CrossRefGoogle Scholar